Results 51 to 60 of about 5,375 (154)

A Framework for XML-based Integration of Data, Visualization and Analysis in a Biomedical Domain [PDF]

open access: yes, 2005
Biomedical data are becoming increasingly complex and heterogeneous in nature. The data are stored in distributed information systems, using a variety of data models, and are processed by increasingly more complex tools that analyze and visualize them ...
Bales, Nathan   +5 more
core   +1 more source

Comparative analysis of real‐world adherence and persistence patterns with vibegron, mirabegron, and anticholinergics in patients with overactive bladder: A retrospective claims study

open access: yesNeurourology and Urodynamics, Volume 43, Issue 7, Page 1504-1513, September 2024.
Abstract Introduction Vibegron is a selective β3‐adrenergic receptor agonist that was approved by the US Food and Drug Administration in December 2020 for the treatment of overactive bladder in adults. This retrospective study assessed US pharmacy claims data to evaluate the real‐world adherence and persistence of vibegron compared with mirabegron and ...
Benjamin Chastek   +8 more
wiley   +1 more source

LAS: a software platform to support oncological data management [PDF]

open access: yes, 2012
The rapid technological evolution in the biomedical and molecular oncology fields is providing research laboratories with huge amounts of complex and heterogeneous data.
A El Akadi   +11 more
core   +1 more source

Onset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study

open access: yesCancer, Volume 130, Issue 16, Page 2812-2821, 15 August 2024.
Abstract Introduction Nirogacestat is a targeted gamma secretase inhibitor approved in the United States for adults with progressing desmoid tumors. In the phase 3 DeFi study (NCT03785964) of nirogacestat, ovarian toxicity (OT) was identified as a safety signal among females of reproductive potential (FORP).
Elizabeth T. Loggers   +9 more
wiley   +1 more source

Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B‐cell lymphoma after 2 or more lines of prior therapy

open access: yesAmerican Journal of Hematology, Volume 99, Issue 5, Page 880-889, May 2024.
Abstract Axicabtagene ciloleucel (axi‐cel) in trials has demonstrated favorable efficacy compared with historical controls after ≥2 lines of therapy for the treatment of relapsed or refractory (R/R) large B cell lymphoma (LBCL). Herein, we compared the real‐world effectiveness of axi‐cel with efficacy and effectiveness of chemoimmunotherapy (CIT) in ...
Matthew A. Lunning   +22 more
wiley   +1 more source

Expert systems and the emergence of teledesign [PDF]

open access: yes, 2001
This paper considers the extent to which the amateur use of expert systems for home design challenges traditional views of the design process. The issues are examined in the context of competing definitions of design.
Crabbe, A
core   +1 more source

Nature‐versus‐nurture considered harmful: Actionability as an alternative tool for understanding the exposome from an ethical perspective

open access: yesBioethics, Volume 38, Issue 4, Page 356-366, May 2024.
Abstract Exposome research is put forward as a major tool for solving the nature‐versus‐nurture debate because the exposome is said to represent “the nature of nurture.” Against this influential idea, we argue that the adoption of the nature‐versus‐nurture debate into the exposome research program is a mistake that needs to be undone to allow for a ...
Caspar W. Safarlou   +3 more
wiley   +1 more source

Electronic clinical practice guidelines: Current status and future prospects in Hong Kong [PDF]

open access: yes, 2003
published_or_final_versio
Cheung, NT, Chim, CS, Fung, H, Wong, KC
core  

Long‐term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trial

open access: yesMuscle &Nerve, Volume 69, Issue 1, Page 93-98, January 2024.
Abstract Introduction/Aims Delandistrogene moxeparvovec is indicated in the United States for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene. Long‐term delandistrogene moxeparvovec microdystrophin protein (a shortened dystrophin that retains key ...
Jerry R. Mendell   +16 more
wiley   +1 more source

Youth Med.Info: a case study in co-design of mental health medicines-information resources for children, young people and their parents/guardians

open access: yesBMJ Open
Objectives To address the lack of accurate and accessible mental health medicines-information resources for children, young people and their parents/guardians using design thinking to co-design free-to-use, video resources tailored to this audience ...
Aoife Carolan   +16 more
doaj   +1 more source

Home - About - Disclaimer - Privacy